{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:31:26Z","timestamp":1761492686015,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jcjd.2014.07.221","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T16:31:13Z","timestamp":1412267473000},"page":"372-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Testing for Albuminuria in 2014"],"prefix":"10.1016","volume":"38","author":[{"given":"Philip A.","family":"McFarlane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2014.07.221_bib1","first-page":"930","article-title":"Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin\/creatinine ratio","volume":"7","author":"Warram","year":"1996","journal-title":"J\u00a0AmSoc Nephrol"},{"key":"10.1016\/j.jcjd.2014.07.221_bib2","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.jcjd.2013.01.037","article-title":"Canadian Diabetes Association 2013 Clinical Practice Guidelines for the prevention and management of diabetes in Canada: Chronic kidney disease in diabetes","volume":"37","author":"McFarlane","year":"2013","journal-title":"Can J Diabetes"},{"issue":"Suppl","key":"10.1016\/j.jcjd.2014.07.221_bib3","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2014.07.221_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2337\/diacare.14.7.591","article-title":"Microalbuminuria: Invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients","volume":"14","author":"Kouri","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.07.221_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2337\/diacare.22.2.307","article-title":"Detection of microalbuminuria: receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration","volume":"22","author":"Bakker","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.07.221_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.ki.5001729","article-title":"Time to abandon microalbuminuria?","volume":"70","author":"Ruggenenti","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2014.07.221_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.ASN.0000051594.21922.99","article-title":"Development of renal disease in people at high cardiovascular risk: Results of the HOPE randomized study","volume":"14","author":"Mann","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jcjd.2014.07.221_bib8","first-page":"B35","article-title":"Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study","volume":"23","author":"Gerstein","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.07.221_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2014.07.221_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.07.221_bib11","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1681\/ASN.2012030252","article-title":"Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jcjd.2014.07.221_bib12","first-page":"S126","article-title":"Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada: Chronic kidney disease in diabetes","volume":"32","author":"McFarlane","year":"2008","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2014.07.221_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/ajkd.2002.31988","article-title":"Different patterns of renal damage in type 2 diabetes mellitus: A multicentric study on 393 biopsies","volume":"39","author":"Mazzucco","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcjd.2014.07.221_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ndt\/gfi163","article-title":"The unrecognized prevalence of chronic kidney disease in diabetes","volume":"21","author":"Middleton","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jcjd.2014.07.221_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ki.2009.399","article-title":"In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria","volume":"77","author":"Perkins","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2014.07.221_bib16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diabetes.52.4.1036","article-title":"Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions","volume":"52","author":"Caramori","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2014.07.221_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.07.221_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.07.221_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.07.221_bib20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.07.221_bib21","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.07.221_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.jcjd.2014.07.221_bib23","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ki.1995.236","article-title":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial","volume":"47","author":"The Diabetes Control and Complications (DCCT) Research Group","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2014.07.221_bib24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.07.221_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jcjd.2014.07.221_bib26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ncpneph0559","article-title":"Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial","volume":"3","author":"Schrier","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jcjd.2014.07.221_bib27","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"De Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2014.07.221_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jcjd.2014.07.221_bib29","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jcjd.2014.07.221_bib30","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.07.221_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.07.221_bib32","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type\u00a02 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267114005231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267114005231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:25:31Z","timestamp":1761492331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267114005231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1499267114005231"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2014.07.221","relation":{},"ISSN":["1499-2671"],"issn-type":[{"type":"print","value":"1499-2671"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testing for Albuminuria in 2014","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2014.07.221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}